+34 620 10 75 37info@nanbiosis.com

Posts Taged 3d-bio-printing

New Center for Research in Advanced Pharmaceutical Development

The NanoBioCel Research group, led by Jose Luis Pedraz, from CIBER-BBN and UPV/EHU, group that coordinates the Unit U10 Drug Formulation of NANBIOSIS -ICTS, together with the Provincial Council of Álava and the Center for Technological Research and Development TECNALIA, have launched last Thursday, January 21, the new Center for Research in Advanced Pharmaceutical Development, which will be located in the Lascaray Building, on the Álava campus of the UPV / EHU.

The objective of this center is to introduce new technologies in the pharmaceutical field and promote applied research in 3D Bio-printing, 3D Printing of medical devices and 3D Printing of new drugs.

This new center is a strategic and ambitious project, supported directly by the Provincial Council of Álava with a budget of € 2,500,000 that seeks to integrate the Álava region within the strategy proposed by the European Union in biosciences and technological development, sectors that have been boosted in the new investment initiative in response to the Coronavirus. This center is also a regional reference as a result of the leadership exercised by the NanoBioCel research group and a fruitful relationship of common projects to offer services to the pharmaceutical industry with Tecnalia2.

In the picture: Jose Luis Elejalde from Tecnalia, Javier Hernando from the Provincial Council of Alava, Pilar Garcia de Salazar, Lieutenant General Deputy and Provincial Deputy for Economic Development and Territorial Balance in the Provincial Council of Alava. Jose Luis Martin, Vice-Rector for Research of the UPV / EHU and Jose Luis Pedraz, IP NanoBioCel group.

Read More

3DBio-impression systems and bio-ink for the regeneration of cartilage and bone

The Nanobiocel Group, coordinator of Unit 10 of NANBIOSIS participate in a public-private collaborative project to reach clinical application in the regeneration of osteochondral lesions, which mainly affect the knee and ankle joints.

The new project is funded by the Challenges-Collaboration program of the Ministry of Economy, Industry and Competitiveness. It has a budget of 691,000 euros for 3 years and the participation of two Spanish companies (Bioibérica and REGEMAT3D), the Higher Council for Scientific Research (CSIC), the University of Granada, the Center for Biomedical Research in Network Bioengineering, Biomaterials and Nanomedicine (CIBER -BBN) and its ICTS NANBIOSIS.

The companies and research groups participating in this project will work in the manufacture of three-dimensional mesh pieces or scaffolding designed with 3D bio-printing systems. These pieces will be fed with cells that make it possible to generate tissues in vitro to regenerate lesions. The ultimate goal is the development of new bio-inks (in which meshes and cells are combined) that are implanted in bone and cartilage.

In addition, the high prevalence of joint injuries makes them very interesting as the first application of bio-printing, with a view to its use in clinical practice”, Explains Patricia Gálvez, director of the Advanced Therapies Unit of Bioibérica, the coordinating company of this project.

A worldwide pioneering project

The company REGEMAT3D has developed a system of devices for bio-pioneering worldwide. This system, intended for research groups in its initial version, allows bio-printing three-dimensional meshes loaded with various cell types (chondrocytes and mesenchymal stem cells) for the regeneration of cartilage. This type of fabric has a number of advantages compared to others because of its relative simplicity, and above all because it is not necessary that a previous cultivation has been carried out.

From the scientific point of view, there are several improvements to be made in the area of ​​3D bio-printing to make this technology so promising can be used in the clinic with guarantees of success. It is necessary to develop new biomaterials for meshes that mimic biological materials with similar mechanical and chemical properties. These biomaterials have to be printable and their parameters have to be controllable. It is also necessary to access a well characterized and reproducible source of cells to feed these pieces that can be obtained in large quantities to be able to repair wide areas of tissue.

For this task, they have joined forces REGEMAT3D, Bioibérica, the Nanobiocel Group of CIBER-BBN, coordinator of Unit 10 of NANBIOSIS, the research group CTS-205 of the Department of Pharmacy and Pharmaceutical Technology and the research group CTS-963 of Advanced Therapies: Differentiation, Regeneration and Cancer, both belonging to the University of Granada and the Biomaterials Group of the Polymer Science and Technology Institute of CSIC, also belonging to CIBER-BBN.

All these companies and research groups contribute with their know how in bio-printing to the development of pharmaceutical products for the treatment of joint injuries, cellular therapies and biomaterials, in a way that constitutes a multidisciplinary consortium with wide guarantees of success.

Nanbiosis - New bioadhesive with 3D printing technique to improve pterygium surgeryLogo FEDER - Nanbiosis

“Promover el desarrollo tecnológico, la innovación y la investigación de calidad”

bioprinted human cells
Read More